Current status
European Commission final decision


Orbax is a veterinary medicinal product for dogs containing orbifloxacin presented in 6.25 mg, 25 mg and 75 mg film-coated tablets. The active substance orbifloxacin is a synthetic broad spectrum antibacterial agent from the class of fluoroquinolone carboxylic acid derivatives. Orbax is intended for use in dogs for the treatment of uncomplicated bacterial cystitis due to susceptible strains of E. coli and Proteus mirabilis and treatment of skin and associated soft tissue infections (wounds and abscesses), associated with bacteria susceptible to orbifloxacin.

The marketing authorisation holder, Schering-Plough Limited, submitted an application for a mutual recognition procedure for Orbax on the basis of the marketing authorisation granted by the United Kingdom. This was an extension application to add the above-mentioned indication for treatment of skin and associated soft tissue infections (wounds and abscesses). The reference Member State is United Kingdom. The concerned Member States are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Luxembourg, the Netherlands, Portugal, Spain and Sweden.

The mutual recognition procedure started on 14 June 2002. Potential serious risks were identified during the mutual recognition procedure by Denmark and Spain regarding the efficacy.

On 12 September 2002, in view of the remaining unsolved issues Denmark and Spain submitted a referral notification under Article 33 of Directive 2001/82/EC to the CVMP.

The referral procedure started on 2 October 2002. The Committee appointed J. Luthman as rapporteur and R. Breathnach as co-rapporteur. Written explanations were provided by the marketing authorisation holder on 15 November 2002.

Based on the evaluation of the available data, the CVMP considered that the objections raised by Denmark and Spain during the mutual recognition procedure should not prevent the granting of a marketing authorisation for Orbax. Therefore, the CVMP adopted a positive opinion on 15 January 2003 recommending the granting of the marketing authorisation the above-mentioned product.

The scientific conclusions are provided in Annex I. The list of product names concerned is given in Annex II, together with the Summaries of Product Characteristics in Annex III.

The opinion was converted into a Decision by the European Commission on 16 April 2003.

Key facts

Approved name
International non-proprietary name (INN) or common name
Current status
European Commission final decision
Reference number
Article 33

Mutual-recognition and decentralised referral: initiated because of disagreement between Member States within the framework of the mutual-recognition or decentralised procedure.

Opinion date
EC decision date

All documents

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. veterinary healthcare professionals, farmers, academia) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of CVMP
  • Divergent positions – divergent positions of the CVMP members (if applicable)
  • Changes to the summary of product characteristicslabelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)

How useful was this page?

Add your rating